Tinengotinib vs chemotherapy for advanced bile duct cancer with FGFR2 changes
Part of Cancer clinical trials.
This study tests a new oral medication (tinengotinib) against standard chemotherapy for people with advanced bile duct cancer that has a specific gene change (FGFR2). Doctors want to see if this drug can help shrink or slow the cancer better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a type of bile duct cancer that starts in the liver (intrahepatic cholangiocarcinoma) that is advanced or cannot be removed with surgery.
- Your cancer came back or progressed after only one first round of chemotherapy combined with immunotherapy (such as PD-1/PD-L1 drugs).
- A lab test must show your cancer has a specific change in the FGFR2 gene.
- You are generally well enough to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
This trial tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. Combining immunotherapy with chemotherapy may help shrink tumors and slow the cancer's growth.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
This trial is testing treatments that are customized to the specific genetic changes in your bile duct or gallbladder cancer. The goal is to find a drug that targets your tumor's unique mutation, which may help control the cancer better than a one-size-fits-all approach.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.